UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | November 3, 2023 4:00 P.M. |
Form: | S-3 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | November 3, 2023 4:00 P.M. |
Form: | S-3 | ||||||
|
SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)
SC 13G - enVVeno Medical Corp (0001661053) (Subject)
SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)
- Conference call with live audio webcast to be held on Wednesday, September 21st at 4:30 PM ETIRVINE, CA / ACCESSWIRE / September 19, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it will host a conference call and webcast on Wednesday, September 21, 2022 at 4:30 PM ET.Interested participants and investors may access the conference call by dialing (877) 407-9708 (domestic) or (201) 689-8259 (international) and referencing conference ID: 13732870. The live webcast will be accessible on the Events page of the Investors section of the enVVeno website, envveno.com, and w
4 - enVVeno Medical Corp (0001661053) (Issuer)
4 - enVVeno Medical Corp (0001661053) (Issuer)
4 - enVVeno Medical Corp (0001661053) (Issuer)
10-Q - enVVeno Medical Corp (0001661053) (Filer)
S-8 - enVVeno Medical Corp (0001661053) (Filer)
10-Q - enVVeno Medical Corp (0001661053) (Filer)
MedTech Marketing Leader with Significant New Product Launch Experience for Cardiovascular DevicesKey Addition to Commercial Team as Company Begins Planning for the VenoValve MonetizationSeveral Upcoming Company Milestones Planned for Q4 of 2024 Including:Completion of PMA Submission Seeking FDA Approval for the VenoValveRelease of One Year Data from VenoValve U.S. Pivotal StudyBeginning of GLP Pre-clinical Study for enVVe in Preparation for enVVe Pivotal Trial IRVINE, CA / ACCESSWIRE / September 3, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Sandy Prietto has
VenoValve PMA Approval Application Process Consists of the Submission of 5 Modules to the FDA4 Modules Have Now Been Submitted, Reviewed, and Approved by the FDACompany on Track to File the 5th and Final Module in Q4 2024 IRVINE, CA / ACCESSWIRE / August 14, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided an update on the U.S. Food and Drug Administration (FDA) premarket approval (PMA) application status for its lead product, a surgical replacement venous valve called the VenoValve. Four (4) out of five (5) modules that comprise the VenoValve PMA application have now bee
- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve®- Positive interim venous ulcer healing data showing significant improvement from the VenoValve pivotal trial presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting- Company on track to file application seeking VenoValve FDA approval in Q4 2024- Continued progress toward launch of GLP study for enVVe® transcatheter-based replacement venous valveIRVINE, CA / ACCESSWIRE / August 1, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the
SRPT: 45% | Sarepeta Therapeutics shares are trading higher after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Also, multiple firms raised their respective price targets on the stock. CLOV: 13% | Clover Health shares are trading higher following the purchase of 877,567 shares by a company director. NVNO: 16% | EnVVeno Medical shares are trading higher after the company reported interim venous ulcer healing data from the SAVVE U.E. pivotal trial for VenoValve, which will be presented at the Society for Vascular Surger
91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed89% of Venous Ulcers with a Duration of More Than One Year Prior to VenoValve Surgery Have Fully Healed or ImprovedNo Ulcer RecurrencesCompany on Track to File Application Seeking VenoValve FDA Approval in Q4 2024
Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Andrew Cormack has been hired as the Company's Chief Commercial Officer. Mr. Cormack, who joined enVVeno Medical on April 8, comes to enVVeno following a career at both start-up and large medical device companies including WallabyPhenox, Medtronic, Covidien,
IRVINE, CA / ACCESSWIRE / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic.Mr. Belteau joined Medtronic as a field engineer upon graduation from college and has progressed through various clinical operations roles over the course of his tenure there. Most recently he managed his own team of clinical operations professionals and has been directly involved is more than 75 clinical st